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•Systematic review and meta-analysis•

Adjunctive melatonin for tardive dyskinesia in patients with
schizophrenia: a meta-analysis
Chen-Hui SUN1#, Wei ZHENG2#, Xin-Hu YANG2, Dong-Bin CAI3, Chee H. NG4, Gabor S. UNGVARI5,6,
Hai-Yan LI2, Yu-Jie WU2, Yu-Ping NING2*, Yu-Tao XIANG7*

Background: Tardive dyskinesia (TD) is characterized by abnormal and involuntary movements. Importantly,
TD could cause considerable personal suffering and social and physical disabilities.
Aims: This meta-analysis based on randomized controlled trials (RCTs) systematically assessed the
therapeutic effect and tolerability of melatonin for TD in schizophrenia.
Methods: A computerized and systematical search of both Chinese (Wanfang Data, Chinese National
Knowledge Infrastructure (CNKI), SINOMED) and English (PubMed, PsycINFO, Embase, Cochrane Library
databases) databases, from their inception until June 8, 2017, was conducted by two independent authors.
The severity of TD symptoms were the primary outcome measure and analyzed using a random effects
model by the Review Manager (RevMan) Version 5.3. Quality evaluation of included RCTs was conducted
using the Cochrane risk of bias and Jadad scale. The GRADE (Grades of Recommendation, Assessment,
Development, and Evaluation) system recommendation grading method was used to assess the overall
quality level of meta-analytic outcomes.
Results: Four RCTs (n=130) were identified and analyzed. Three RCTs used double blind and 1 RCT used
masked assessors using the Cochrane risk of bias, and 3 RCTs were rated as high quality based on Jadad
scale. Compared with the control group, adjunctive melatonin was superior in reducing the severity of TD as
measured by the Abnormal Involuntary Movement Scale (AIMS) (4 RCTs, n=130, weighted mean difference
(WMD): -1.52 (95% confidence intervals (CI): -3.24, 0.20), p=0.08; I2=0%) although the improvement did
not reach a significant level. The overall evidence quality of the improvement of TD symptoms, according to
GRADE approach, was rated as “Low”. The data on the ADRs and cognitive effect were limited.
Conclusions: This meta-analysis shows that melatonin has potential for improving TD symptoms in
schizophrenia. Future higher quality and larger RCTs are warranted to confirm the findings.
Review registration: CRD 42016049698 (http://www.crd.york.ac.uk/PROSPERO/)
Key words: Tardive dyskinesia; antipsychotic; melatonin; meta-analysis
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1. Introduction
Tardive dyskinesia (TD) can occur in up to 20%
of schizophrenia patients receiving long-term
antipsychotics (APs) [1-4] , and is associated with
considerable personal suffering and social and physical
disabilities. [3] TD is characterized by abnormal and
involuntary movements (such as choreiform, athetoid
and rhythmic) on orofacial, extremities, or even
truncal region.[5] Numerous medications for TD have
been examined, but there have been no well-proven
treatments.[6]
The pathophysiology of APs induced TD remains
controversial. Free radicals associated with low brainderived neurotrophic factor (BDNF) is probably involved
in the process.[2,7,8] Several antioxidants, based on the
free radical hypothesis of TD, have been studied for
the therapeutic effects of TD, such as melatonin[6,9-11],
vitamin B6[12,13], vitamin E[14,15], Ginkgo biloba (EGb)[4] and
piracetam.[16,17]
Melatonin (N-acetyl-5-methoxytryptamine), a
neurohormone that is secreted by the pineal gland, is a
naturally occurring potent antioxidant in the brain.[5,18]
Animal model studies[19-21] suggested that melatonin is
efficacious in the improvement of abnormal movements.
Some randomized controlled trials (RCTs)[6,9-11] have
examined the efficacy and safety of adjunctive
melatonin for schizophrenia patients with TD, but
results are inconsistent.
One review [5] which examined the efficacy of
melatonin for schizophrenia patients with TD based
on only two RCTs[10,11] used qualitative analysis without
adequate assessment of study quality. Hence, the
objective of this RCT meta-analysis was to systematically
assess the efficacy and safety of adjunctive melatonin
therapy for TD in schizophrenia using both English and
Chinese databases since the latter is not widely known
internationally.
2. Methods
2.1 Search Strategy and Selection Criteria
Two authors (WZ and D-BC) independently and
systematically searched English (PubMed, PsycINFO,
Embase, Cochrane Library databases) and Chinese
databases (Wanfang Data, Chinese National Knowledge
Infrastructure (CNKI), SINOMED), with each database
from their inception until June 8, 2017, using the
following search terms: (Tardive Dyskinesia OR
Dyskinesia*, Tardive OR Dyskinesias, Tardive OR
Dystonias, Tardive) AND (Mélatonine OR Melatonin).
Reference lists of all identified RCTs and relevant review
articles[5] for additional studies were also hand-searched.
The following selection criteria were presented
using the PICOS acronym: Participants: adult
schizophrenia patients with TD (≥18 years) by any
diagnostic criteria. Intervention: melatonin combined
with APs. Comparison: APs combined with placebo or
APs monotherapy. Outcomes: the primary outcome
measure was the severity of TD symptoms at endpoint
assessment measured by the Abnormal Involuntary
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Movement Scale (AIMS).[22,23] Key secondary outcomes
were cognitive function, adverse drug reactions (ADRs),
and discontinuation rate. Study design: RCTs with metaanalyzable data.
The literature from the above databases was
screened by two independent authors (WZ and D-BC)
using EndNote X6 software. Figure 1 presents the
literature screening process. Any disagreement during
this process was resolved through a discussion.
2.2 Data extraction
Two authors (D-BC and X-HY) independently and
systematically extracted data and conducted quality
assessment of included RCTs. Any disagreement was
resolved through a discussion and consensus. Data were
extracted into standard forms. Whenever data were
missing for the meta-analysis, first or correspondence
authors were contacted by email or telephone for
additional information if possible.
2.3 Statistical methods
According to the guidelines from the Preferred
Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) statement[24], we used the Review
Manager (RevMan) Version 5.3 (http://tech.cochrane.
org/revman/) to perform this meta-analysis in cases
that continuous data followed normal distribution
(i.e., the mean > 2 times the standard deviation when
the minimum value was 0). A sensitivity analysis was
conducted by excluding skewed data. For meta-analytic
pooling of continuous and dichotomous outcomes,
the Inverse-Variance method and Mantel-Haenszel
test were used to present weighted mean differences
(WMDs) and risk ratios (RRs) with their 95% confidence
intervals (CIs), respectively. Intention-to-treat (ITT) data
over observed cases (OC) data were preferred when
both were provided. In order to compensate for study
heterogeneity, the random effect model was used in
all meta-analyzable outcomes.[25] Heterogeneity was
presented by I-squared statistic. When I-square was
greater than 50%, sensitivity, subgroup and metaregression analyses were conducted to detect the
sources of heterogeneity. Furthermore, data of primary
outcome were entered into a funnel plots or analyzed
using Egger’s test[26] to test Publication bias. All analyses
were two tailed, with significance level set at 0.05.
2.4 Assessment of study quality
The methodological quality of the RCTs was assessed
using the Cochrane risk of bias assessment tool[27] with 7
dimension as follows: (a) random sequence generation;
(b) allocation concealment; (c) blinding of the subjects
and the treatment providers; (d) blinding of the result
evaluators); (e) incomplete results data; (f) selective
reporting; (g) other potential risks. Furthermore, the
Jadad scale was used to assess study quality.[28] High
and low quality of included RCTs were defined as Jadad
score ≥3 and <3, respectively. In addition, the overall
evidence quality of all meta-analyzable outcomes was
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rated as “very low “, “low”, “moderate “ and “high”
by two independent authors (WZ and D-BC) using the
grading of recommendations assessment, development,
and evaluation (GRADE) system.[29,30]
3. Results
3.1 Results of the search
Figure 1 presents a flow chart of article selection from
English (n=206) and Chinese databases (n=10). Finally,
4 RCTs (Castro 2011; Shamir 2000; Shamir 2001; Zhu
2010) were eligible and included for the meta-analysis
(Figure 1).
3.2 The characteristics of included studies
Three double-blinded trials (Castro 2011; Shamir 2000;
Shamir 2001) and one rater masked trial (Zhu 2010)
compared adjunctive melatonin (n=67) and control
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groups (n=63) (Table 1). The weighted mean treatment
duration was 9.8 weeks (range=4-12 weeks) (Table
1). Of the 4 RCTs , two RCTs (Shamir 2000; Shamir
2001) were conducted in Israel (n=41), one in China
(Zhu 2010, n=76) and one in Venezuela (Castro 2011,
n=13), respectively. While 24 patients in Shamir 2001
were eligible, 22 patients were described and analyzed
because 2 patients were discharged from the hospital
before initiation of the study.
3.3 Patient characteristics
The weighted mean age was 61.3 years (range =57.674.0 years) (Table 1), the percentage of males was
41.54% (range=34.2%-69.2%), and the weighted
mean illness duration in 3 RCTs (Castro 2011; Shamir
2000; Shamir 2001) with available data was 28.6
years (range=24.8-31.3 years). The RCTs (n=130) were
conducted in inpatient (n=119, 91.5%) and outpatient

Figure 1. Identification of included studies
216 articles published before Jun 8, 2017 were identified using a standard search strategy and other sources
(see methods section):
•
4 from Chinese National Knowledge Infrastructure
•
4 from WanFang Data
•
2 from SINOMED
• 44 from PubMed
• 29 from PsycINFO
•
9 from Cochrane Library databases
• 124 from Embase
45 duplicates removed

171 unduplicated studies: 10 published in Chinese, 161 in English
160 articles excluded based on title and abstract
11 full-text articles assessed for eligibility
7 full-text articles excluded:
• 1 review
• 5 animal trials
• 1 data based on same sample

4 studies included in qualitative synthesis

4 studies included in quantitative synthesis
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(n=3, 2.3%) and rehabilitation institution settings (n=8,
6.2%).

drug company sponsorship) were rated as low risk and
unclear in all included RCTs.

3.4 Treatment characteristics
The weighted mean dosage of melatonin dosage
was 9.2 mg/day (range=2.0-20.0 mg/day). One RCT
(Zhu 2010) did not report details of APs use, but the
remaining RCTs (Castro 2011; Shamir 2000; Shamir 2001)
reported using a range of APs including levopromazine,
haloperidol, clozapine, aripiprazole, olanzapine,
quetiapine, risperidone, perphenazine, zuclopenthixol
and chlorpromazine. Furthermore, the mean dosage of
mixed APs in the 3 RCTs with available data was 262.3
mg/day in chlorpromazine dose equivalents. Only one
RCT (Castro 2011) reported the study funding sources.

3.6 Jadad scale
The weighted mean Jadad total score of the 4 RCTs was
2.4 (range=1-5). While one RCT (Zhu 2010) was classified
as low quality, 75% RCTs (n=3) (Castro 2011; Shamir
2000; Shamir 2001) were rated as high quality.

3.5 Risk of bias
One RCT (Shamir 2001) mentioned “random”
assignment with specific description, 3 RCTs (Castro
2011; Shamir 2000; Shamir 2001) used double blind
and 1 RCT (Zhu 2010) used masked assessors (Table 2).
Two RCTs (Shamir 2000; Shamir 2001) were rated as
low risk regarding the allocation concealment methods
and the potential for selective reporting. Incomplete
outcome data addressed and other sources of bias (e.g.,

3.7 Primary outcome
The improvement of TD symptoms: there were
differences between the two groups in terms of the
AIMS total score (4 RCTs) at the treatment endpoint.
Adjunctive melatonin was superior in reducing the
severity of TD symptoms (4 RCTs, n=130, WMD:
-1.52 (95%CI: -3.24, 0.20), p=0.08; I2=0%, Figure 2)
when compared to the control group although the
improvement did not reach a significant level. The
results remained after removing two trials (Shamir
2001 and Zhu 2010) with non-normal distributions data
(WMD: -2.70 (95%CI: -6.58,1.19, p=0.17; I2=0%). Due
to the limited number of RCTs, risk of publication bias
could not be examined. The overall evidence quality of
the improvement of TD symptoms was rated as “Low”
(table 3).

Table 1. Characteristics of the included studies
study
(Country)

N

Castro
13
2011[9]
(Venezuela)
Shamir
2000[10]
(Israel)
Shamir
2001[11]
(Israel)
Zhu
2010[6]
(China)
a

19
22

76

Design:
-Blinding
-Setting

Participants:
Agea: Sexa:
-Diagnosis
yrs
Male
-Criteria
(range)
(%)
-Illness duration

Interventions:
Duration Jadad
-Mean dose (mg/day) -Trial
(wks)
-Range (mg/day)
score
-Number of patients -Outcomes

-Double blind
-Inpatients (15%)
and outpatient
settings (23%) and
a rehabilitation
institution (62%)
-Double blind
(crossover)d
-Inpatients (100%)
-Double blind
(crossover)c
-Inpatients (100%)

-TD
-DSM-IV-TR
-30.9 yrs

APsb (M=400c) + MEL
59.9
n=9
(20 c); n=7
(46-75) (69.2%) APs
b
(M=400c); n=6

-TD
-DSM-IV
-31.3 yrs
-TD
-DSM-IV
-24.8 yrs

APse (M=238c) +
74.0
n=8
c
); n=9
(55-91) (42.1%) MEL(2
APse (M=238c); n=10
APsf (M=202c) + MEL
64.2
n=11
c
(28-82) (50.0%) (10 f); n=12 c
APs (M=202 ); n=10

-Single blind
-Inpatients (100%)

-TD
-CCMD-3
NA

57.6
(NA)

APsg (M=NA) + MEL
n=26
(9c); n=39
(34.2%) APs
g
(M=NA); n=37

-12
-AIMS

4

-4
-AIMS

4

-6
-AIMS

5

-12
-AIMS; TESS;
WAIS; WMS;
VFT; RBANS

1

Mean baseline.
Including levopromazine, haloperidol, clozapine, aripiprazole, olanzapine, quetiapine and risperidone.
c
Mean dose of APs (in chlorpromazine equivalents) or fixed dosage of MEL.
d
We only extracted data from the first phrase.
e
Including haloperidol, perphenazine and zuclopenthixol.
f
Including haloperidol, perphenazine, zuclopenthixol and chlorpromazine.
g
Failed to report detailed use of antipsychotics.
APs=antipsychotics; AIMS=Abnormal Involuntary Movement of Scale; CCMD-3=China’s Mental Disorder Classification and Diagnosis
Standard 3th edition; CPZ-equ= chlorpromazine equivalents; DSM-IV=Diagnostic and Statistical Manual of Mental Disorders 4th edition;
DSM-IV-TR=Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision; M=mean; MEL=melatonin; NA=not
available; RBANS=Repeatable Battery for the Assessment of Neuropsychological Status; TESS=Treatment Emergent Symptom Scale;
VFT=Verbal fluency test; yrs=years; WAIS=Wechsler Adult Intelligence Scale; WMS=Wechsler Memory Scale; wks=Weeks.
b
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Table 2. Evaluation of risk of bias in the included studies
allocation
blinding of
sequence
sequence
participants
generation concealment
and personnel

study
Castro 2011[9]

blinding of
outcome
assessment

incomplete
outcome
data

selective
other
outcome potential threats
reporting
to validity

N/A

N/A

low

low

low

N/A

N/A

[10]

N/A

low

low

low

low

low

N/A

[11]

low

low

low

low

low

low

N/A

high

N/A

high

low

low

N/A

N/A

Shamir 2000
Shamir 2001
[6]

Zhu 2010

N/A=no information available

Table 3. Adjunctive Melatonin for Tardive Dyskinesia: GRADE assessments
Outcomes

number of studies
(pooled sample)

Effectiveness

4 (130)

test for
test for
heterogeneity Analytic overall effect
model
I2
p
z
p
0%

0.89

random 1.73

0.08

estimate
-1.52(WMD)

95%confidence
interval of estimate GRADE
-3.24 to 0.20

Low

GRADE=Grades of Recommendation, Assessment, Development, and Evaluation; WMD=weighted mean difference

3.8 Secondary outcomes
Cognitive function: One RCT (Zhu 2010) assessed the
cognitive effects of the melatonin treatment (Table 4).
Adjunctive melatonin outperformed the control group in
the Wechsler Adult Intelligence Scale-Revised, Chinese
version (WAIS-RC) [including verbal scale, performance
scale and full scale total scores], Verbal Fluency Test
(VFT) [including animal, fruit, and word and Repeatable
Battery for the Assessment of Neuropsychological
Status (RBANS) [including verbal fluency]. In terms of
cognitive function assessed by the Wechsler Memory
Scale (WMS), no difference was found between the two
groups (total score and memory quotient of WMS).
ADRs: Only one RCT (Zhu 2010) assessed ADRs using
the Treatment Emergent Symptom Scale (TESS), and no
group difference was found (Table 4).

Discontinuation rate: Regarding discontinuation
rate, one RCT (Shamir 2001) reported that 2 patients
were discharged before the randomization.
4. Discussion
4.1 Main findings
Previously only one review [5] with 2 RCTs (n=41)
involved the therapeutic effects and safety of adjunctive
melatonin for schizophrenia patients suffering from
TD, finding an advantage of melatonin in improving
the severity of TD symptoms. In this meta-analysis (4
RCTs, n=130) based on English and Chinese databases,
the results showed that adjunctive melatonin
outperformed the control group in treating the severity
of TD symptoms although the improvement did not

Figure 2. Adjunctive Melatonin for Tardive Dyskinesia (TD): Forest plot for the endpoint score of the Abnormal
Involuntary Movement of Scale
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Table 4. Adjunctive Melatonin for Tardive Dyskinesia: Cognitive Function at endpoint and ADRs
Secondary
outcomes

Studies

Cognitive
function

Zhu 2010

ADRs

Zhu 2010

Scale of
assessment

Findings

Adjunctive melatonin outperformed the control group in the WAIS-RC
verbal scale, performance scale and full scale total scores), VFT
WAIS-RC; WMS; (including
(including
animal, fruit, and word) and RBANS (including verbal fluency).
VFT; RBANS
No significant effects for other domains (including total score and memory
quotient of WMS).
TESS
Not significant

ADRs=adverse drug reactions; RBANS=Repeatable Battery for the Assessment of Neuropsychological Status; TESS=Treatment Emergent
Symptom Scale; VFT=Verbal Fluency Test; WAIS-RC= Wechsler Adult Intelligence Scale-Revise, Chinese version; WMS=Wechsler Memory
Scale.

reach significance level. The strengths of this metaanalysis are the inclusion of two additional RCTs[6,9] and
the inclusion of Chinese databases with low quality. In
addition, quality assessment of included studies using
the Cochrane risk of bias[27] and Jadad scale[28] were
conducted. The overall quality level of primary outcome
were rated as “Low” using the GRADE approach.
However, the data on the ADRs and cognitive effect
were only reported in one RCT (Zhu 2010), which limits
our capacity to conduct meta-analysis.
Possible mechanism of melatonin in improving TD
could be due to its potent antioxidant properties, which
reduces oxidative stress, enhances BDNF levels and
decreases the chance of neurotoxicity.[5] Furthermore,
Zisapel’s study[31] suggested that melatonin inhibits
dopamine release in specific areas of the mammalian
central nervous system (including retina, hypothalamus,
medulla-pons, and hippocampus). Thus, melatonin
could modulate dopaminergic pathways associated with
movement disorders including TD.
4.2 Limitations
First, the sample sizes were relatively small and some
information was limited, which failed to bring about a
robust result.[32] Second, the dose-response effect of
adjunctive melatonin (2 to 20mg/day) on TD symptoms
could not be evaluated. Third, since all included RCTs
were of short duration, ranging from 4 to 12 weeks,
the long-term effects of melatonin on TD need to be
examined further. Finally, we made a minor correction in
the methods and made it differ from the protocol of this
meta-analysis, i.e., “only randomized double blinded
controlled trials were included” was changed to “only
randomized controlled trials were included”.
4.3 Implications
TD is irreversible, severe, and disabling, and so far no
therapeutic strategies have been approved by the Food
and Drug Administration (FDA). One meta-analysis
of adjunctive EGb (ginkgo)[4] including 3 RCTs found
adjunctive EGb could significantly reduce the severity of
TD symptoms in schizophrenia. Another meta-analysis
found that while adjunctive vitamin E[15] was similar with
placebo in improving TD symptoms, it could significantly

slow down the progression of the severity of TD
symptoms in schizophrenia. Moreover, the previous
systematic review [5] has explored the therapeutic
effects of adjunctive melatonin, piracetam, and vitamin
B6 on TD in schizophrenia. If melatonin is shown to
be effective in TD, it may be a readily accessible and
affordable option. However, future higher quality and
larger RCTs are needed to confirm these results.
4.4 Conclusion
This meta-analysis shows that melatonin has potential
for improving TD symptoms in schizophrenia. However,
higher quality and larger RCTs are needed to confirm
these findings, especially focusing on long-term
therapeutic effects.
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褪黑素治疗精神分裂症患者迟发性运动障碍的 meta 分析
孙辰辉，郑伟，杨欣湖，蔡东滨，Ng CH，Ungvari GS，李海燕，吴玉洁，宁玉萍，项玉涛

背景 : 迟发性运动障碍 (TD) 的临床特征是异常不自主
运动。TD 具有严重的不可逆的致残性和社会功能损害。
目的 : 此荟萃分析基于随机对照试验 (RCTs) 文献系统
评估褪黑素对精神分裂症患者迟发性运动障碍的临床
疗效和安全性。
方法 : 两位独立评估者从以下数据库对相关的临床随
机对照试验（RCT）文献进行检索 ( 万方数据、中国
知网 (CNKI)、中国生物医学文摘数据库和 PubMed、
PsycINFO、Embase、Cochrane Library 数据库 ) ，检索时
间截止于 2017 年 6 月 8 日。以 TD 症状严重程度为主
要结局指标，采用 Rev Man 5.3 版本进行统计分析，对
RCTs 的质量评估采用 Cochrane 风险评估偏倚和 Jadad
量表来评估各种偏倚的风险性。采用 GRADE(Grades
of Recommendation, Assessment, Development, and
Evaluation) 系统推荐分级方法对 meta- 分析结果的整体
证据质量水平进行分级评价。

结果 : 最终筛选确定 4 个 RCTs(n = 130)。3 个 RCTs 采
用双盲法，1 个 RCT 单盲，根据 Cochrane 风险评估偏
倚和 Jadad 量表显示 3 个 RCTs 的疗效评估指标的证据
质量被评定为 “ 高质量 ”。与对照组相比，根据不自
主运动量表 (AIMS) 评定褪黑素可改善 TD 严重程度 (4
个 RCTs, n = 130，加权平均差值 (WMD):-1.52(95%CI: 3.24,0.20), p = 0.08; I2 = 0%)，但尚没有达到显著差异。
根据等级方法，改善 TD 症状的 meta 分析结果的整体
证据质量被评为 “ 低 ”，而关于不良反应和认知损害方
面则数据太少。
结论 : 荟萃分析表明，褪黑素或可改善精神分裂症 TD
症状。但仍有待今后更高质量和更大样本的 RCTs 验证。
关键词 : 迟发性运动障碍 ; 抗精神病药 ; 褪黑素 ; 荟萃

分析
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